The controversial results on the role of CXCR3 ligands in pancreatic cancer could also be explained by the fact that a subset of cancer cells in pancreatic cancer express CXCR3 and that the exposure to CXCL10 promotes resistance to gemcitabine [19]. This evidence concerns the gene CXCR3 and familial pancreatic carcinoma.